Several clinical trials using XR-9576 in combination with chemotherapy revealed that XR-9576 is a potent P-GP antagonist without significant side effects [69–72], representing XR-9576 as a promising treatment for MDR bladder cancer with ectopic BMI1 expression. Here, PGP is linked to urinary bladder carcinoma.